Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
iph-2101 mhc class i nk cell receptor 2dl1 NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]		 6.37 phase 2 inhibitor
iph-2101 mhc class i nk cell receptor 2dl2 NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]		 19.1 phase 2 inhibitor
iph-2101 mhc class i nk cell receptor 2dl2 NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]		 19.1 phase 2 unknown
iph-2101 mhc class i nk cell receptor 2dl3 NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]		 19.1 phase 2 inhibitor
iph-2101 mhc class i nk cell receptor 2dl3 NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]		 19.1 phase 2 unknown
iph-2101 mhc class i nk cell receptor 2ds1 NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]		 25.46 phase 2 unknown
iph-2101 mhc class i nk cell receptor 2ds2 NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]		 25.46 phase 2 unknown
click here to return to the previous page